-

01:27:20 PM

ATHX Stock News

ATHX - Athersys Inc

05/20/22 3:00 AM

Nasdaq : ATHX

Athersys Announces That Its Partner, HEALIOS K.K., Reported Topline Data From the TREASURE Multistem Ischemic Stroke Study

Athersys, Inc. announced today that its partner, HEALIOS K.K., has reported topline results for its Japan ischemic stroke study, TREASURE. The trial enrolled 206 patients and was conducted by 48 sites in Japan. “We are enthusiastic about the topline results from the TREASURE ischemic stroke trial in Japan,” remarked Dan Camardo, Chief Executive Officer of Athersys,...

RHEA-AI

very positive

05/13/22 8:00 AM

Nasdaq : ATHX

conferences

Athersys to Participate in the H.C. Wainwright Global Investment Conference

Athersys, Inc., announced today that Dan Camardo, Chief Executive Officer, will participate virtually in the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, Florida. Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of...

RHEA-AI

neutral

05/06/22 8:00 AM

Nasdaq : ATHX

Athersys Reports First Quarter 2022 Results

Athersys, Inc. announced today its financial results for the three months ended March 31, 2022. In anticipation of the announcement in May of topline data from Athersys’ partner, HEALIOS K.K., for its Phase 2/ 3 TREASURE study evaluating MultiStem ® for the treatment of ischemic stroke, Athersys will host its next investor conference call after the data are...

RHEA-AI

positive

05/02/22 9:00 AM

Nasdaq : ATHX

conferences

Athersys to Participate in the Bank of America Securities 2022 Global Healthcare Conference

Athersys, Inc., announced today that Dan Camardo, Chief Executive Officer, and Ivor Macleod, Chief Financial Officer, will participate in a fireside chat at the Bank of America Securities 2022 Global Healthcare Conference on Wednesday, May 11, 2022 at 4:00 p.m. PT in Las Vegas. Athersys is a biotechnology company engaged in the discovery and development of...

RHEA-AI

neutral

04/29/22 9:00 AM

Nasdaq : ATHX

earnings

Athersys to Announce First Quarter Financial Results on May 6

Athersys, Inc. today announced that it will release its first quarter 2022 financial results on Friday, May 6, 2022, at 8:00 a.m. EDT. In anticipation of the announcement of topline data from Athersys’ partner, HEALIOS K.K., for its Phase 2/ 3 TREASURE study evaluating MultiStem ® for the treatment of ischemic stroke in May, Athersys will host its next investor...

RHEA-AI

neutral

04/04/22 6:00 AM

Nasdaq : ATHX

Athersys Reports That Its Partner, HEALIOS K.K., Provides Updates on MultiStem® Clinical Programs in Japan

Athersys, Inc. announced today that its partner, HEALIOS K.K., has provided updates on its two clinical programs evaluating MultiStem ® cell therapy, for which Healios has a license and is responsible for the development and commercialization of MultiStem for ischemic stroke and acute respiratory distress syndrome in Japan on an exclusive basis.

RHEA-AI

very positive

04/01/22 4:46 PM

Nasdaq : ATHX

conferences

Athersys to Participate in Two Upcoming Investor Conferences

Athersys, Inc. announced today that William Lehmann, President and Chief Operating Officer, will present a corporate overview at the virtual Locust Walk Stem Cell Conference on Monday, April 11, 2022 at 2:00 p.m. ET. Additionally, Dan Camardo, Chief Executive Officer, will present a corporate overview at the 21 st Annual Needham Virtual Healthcare Conference...

RHEA-AI

neutral

03/15/22 4:05 PM

Nasdaq : ATHX

earnings

Athersys Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

Athersys, Inc. announced today its financial results for the three months and full year ended December 31, 2021, along with a corporate update. Daniel A. Camardo, Athersys’ new Chief Executive Officer as of February 14, 2022, commented,“ I’ m excited to be leading Athersys at such a pivotal time as I believe we have the potential to be a global leader in cell therapy and...

RHEA-AI

positive

02/17/22 4:30 PM

Nasdaq : ATHX

Athersys Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Athersys, Inc. announced today that, as previously disclosed in its Form 8- K filed with the Securities and Exchange Commission on January 21, 2022, the Company made an inducement grant to Daniel Camardo, the newly-appointed Chief Executive Officer of Athersys. The option was granted outside of the Athersys, Inc. 2019 Equity and Incentive Compensation Plan as...

RHEA-AI

very positive

02/15/22 8:00 AM

Nasdaq : ATHX

conferencesearnings

Athersys to Host Year-End 2021 Financial Results Call

Athersys, Inc. will release its fourth quarter and full year 2021 financial results on Tuesday, March 15, 2022, after the close of the U.S. financial markets. Mr. Camardo joined the company as CEO on February 14, 2022. Mr. Camardo comes to Athersys at a pivotal time to lead the Company’ s transition to a commercial biopharmaceutical company and leader in cell therapy.

RHEA-AI

neutral

ATHX Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.athersys.com
CeoGil Van Bokkelen
Security nameAthersys Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees97
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address3201 Carnegie Ave
StateOhio
CityCleveland
Zip44115-2634
CountryUS
Phone12164319900

About Athersys Inc

Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived 'off-the-shelf' stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization.